OCULAR THERAPEUTIX, INC Proceeds from Convertible Debt
OCULAR THERAPEUTIX, INC (OCUL) reported Proceeds from Convertible Debt of $37.27 million for the 12-month period ending 2019-12-31, per its 10-K filed 2022-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2022-02-28
- OCULAR THERAPEUTIX, INC proceeds from convertible debt for the quarter ending 2019-12-31 was $0.00.
- OCULAR THERAPEUTIX, INC proceeds from convertible debt for the quarter ending 2019-09-30 was $0.00.
- OCULAR THERAPEUTIX, INC proceeds from convertible debt for the quarter ending 2019-06-30 was -$70.00K.
- OCULAR THERAPEUTIX, INC proceeds from convertible debt for the quarter ending 2019-03-31 was $37.34M.
- OCULAR THERAPEUTIX, INC proceeds from convertible debt for fiscal 2019 was $37.27M.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | -$70.00K derived: sum of 3 quarters · filed 2022-02-28 | $37.27M 10-K · filed 2022-02-28 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$70.00K derived: sum of 2 quarters · filed 2020-11-05 | $37.27M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $37.27M 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $37.34M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |